ORIC Pharmaceuticals, Inc. (ORIC) Tops Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ORIC Pharamceuticals (ORIC) PT Lowered to $14 at Citi
May 7, 2024 5:47 AM EDTCiti analyst Yigel Nochomovitz lowered the price target on ORIC Pharamceuticals (NASDAQ: ORIC) to $14.00 (from $15.00) while maintaining a Buy rating.
The analyst comments "
The 1Q24 update was incrementally informative and most immediately in mid-2024 ORIC is expecting to initiate clinical combination... More
